clinical trial · NCT04573023
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
JCR Pharmaceuticals Co., Ltd.·phase3·active not recruiting·n = 86
Mucopolysaccharidosis IIJR-141IdursulfaseJR-141 or Idursulfase
brief summary
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
started
Feb 14, 2022
primary completion
Oct 31, 2027
completion
Oct 31, 2027
last updated
Apr 21, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol